Get the Stockscreener App
3.565
8.26%
0.295
Nrx Pharmaceuticals Inc stock is traded at $3.565, with a volume of 980.09K.
It is up +8.26% in the last 24 hours and down -17.10% over the past month.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
See More
Previous Close:
$3.27
Open:
$3.1
24h Volume:
980.09K
Relative Volume:
0.78
Market Cap:
$152.58M
Revenue:
$1.23M
Net Income/Loss:
$-28.62M
P/E Ratio:
-2.271
EPS:
-1.5698
Net Cash Flow:
$-14.11M
1W Performance:
+5.67%
1M Performance:
-17.10%
6M Performance:
+96.67%
1Y Performance:
+22.49%
1-Day Range:
$3.09
$3.67
1-Week Range:
$3.09
$3.67
52-Week Range:
$1.62
$5.055
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
Name
Nrx Pharmaceuticals Inc
Sector
Industry
Phone
484-254-6134
Address
1201 ORANGE STREET, WILMINGTON
Compare NRXP vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
3.565 | 139.96M | 1.23M | -28.62M | -14.11M | -1.5698 |
VRTX
Vertex Pharmaceuticals Inc
|
515.31 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.34 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
992.59 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
215.54 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.30 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Nrx Pharmaceuticals Inc Stock (NRXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-25 | Initiated | H.C. Wainwright | Buy |
| Apr-02-25 | Initiated | BTIG Research | Buy |
Nrx Pharmaceuticals Inc Stock (NRXP) Latest News
NRX Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
NRx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET - Investing News Network
NRX Pharmaceuticals Q2 Results: EPS Misses Estimate, Sales Fall 94% - scanx.trade
NRX Pharmaceuticals reports $18.0M net loss for first half 2026, $26.7M cash on hand - TradingView
Five million ketamine doses are in production—but when can sales start? - Stock Titan
NRx Pharmaceuticals, Inc. (NRXP) reports Q2 loss, misses revenue estimates - FXStreet
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
NRx Pharmaceuticals (NASDAQ:NRXP) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
NRx Pharmaceuticals (NASDAQ:NRXP) Issues Earnings Results, Misses Estimates By $0.35 EPS - MarketBeat
NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
NRx Pharmaceuticals (NRXP) grows clinic revenue, flags going concern risk - Stock Titan
NRXP Stock Price, Quote & Chart - ChartMill
NRX Pharmaceuticals Inc expected to post earnings of 6 cents a shareEarnings Preview - TradingView
NRXP Q2'26 Earnings: EPS estimate is (0.11) USD - TradingView
NRX Pharmaceuticals Inc (NRXP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
GOOGL Stock Price TodayAlphabet Inc Class A News, Charts, Retail Sentiment - Stocktwits
H.C. Wainwright reiterates NRx Pharmaceuticals stock rating at buy By Investing.com - Investing.com UK
NRx Pharmaceuticals Nears FDA Decision on Preservative-Free Ketamine After Review Clears Hurdles - MarketBeat
Transcript : NRx Pharmaceuticals, Inc.Special Call - marketscreener.com
H.C. Wainwright reiterates NRx Pharmaceuticals stock rating at buy - Investing.com
NRx Pharmaceuticals (NRXP) Projected to Post Quarterly Earnings on Monday - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: NRX Pharmaceuticals (NRXP), Novo Nordisk (NVO) and Pfizer (PFE) - The Globe and Mail
NRx Advances FDA Review of Ketamine ANDA Packaging Issue - The Globe and Mail
NRX Pharmaceuticals Inc (NRXP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NRx Pharmaceuticals completes FDA first-cycle ANDA review By Investing.com - Investing.com South Africa
NRx Pharmaceuticals to discuss FDA review and c... - Pluang
NRx Pharmaceuticals to Host Conference Call on FDA First-Cycle Review of Preservative-Free Ketamine ANDA - Quiver Quantitative
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans - The Manila Times
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference - GlobeNewswire
NRx Pharmaceuticals Shares Rise After FDA Finishes Ketamine Review - Moomoo
BTIG Research Cuts NRx Pharmaceuticals (NASDAQ:NRXP) Price Target to $10.00 - MarketBeat
FDA Clears Major Regulatory Hurdle as Preservative-Free Ketamine Program Moves Within Reach of Commercialization: NRx Pharmaceuticals: (NAS DAQ: NRXP) - FinancialContent
NRx Pharma rises on FDA review of ketamine ANDA (NRXP:NASDAQ) - Seeking Alpha
NRX Pharmaceuticals Inc. R (B1Q.MU) Q1 FY2026 earnings call transcript - Yahoo Finance
NRx Pharmaceuticals completes FDA first-cycle ANDA review - Investing.com
FDA Completes First-Cycle Review of Preservative-Free - GlobeNewswire
Certain Warrants of NRx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 3-AUG-2026. - marketscreener.com
12 Health Care Stocks Moving In Friday's After-Market Session - Sahm
NRX Pharmaceuticals Inc (NRXP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NRX Pharmaceuticals Market Sentiment - Benzinga España
NRX Pharmaceuticals Inc (NRXP) Valuation: PE, PB & Fair Value Analysis - TradingKey
NRX Pharmaceuticals Inc (NRXP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NRX Pharmaceuticals Inc (NRXP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NRX Pharmaceuticals Inc (NRXP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NRX Pharmaceuticals Inc (NRXP) Cash Flow - TradingKey
NRXP|NRX Pharmaceuticals Inc|Price:3.340|Chg%:-0.020 - tradingkey.com
TradingKey - TradingKey
NRX Pharmaceuticals, Inc. Revenue Breakdown – MUN:B1Q - TradingView
NRX Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:NRXP - TradingView
NRX Pharmaceuticals, Inc. Revenue Breakdown – FWB:B1Q - TradingView
NRX Pharmaceuticals Inc (B1Q.HM) stock price, news, quote and history - Yahoo Finance UK
Nrx Pharmaceuticals Inc Stock (NRXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):